论文部分内容阅读
Actelion公司近日宣称,其研发的新型内皮素受体拮抗剂macitentan在一项名为SERAPHIN的Ⅲ期临床研究中达到主要考察指标。该项大型随机、对照研究将742名肺动脉高压(PAH)患者按1∶1∶1的比例随机分为安慰剂组和
Actelion recently announced that its research and development of new endothelin receptor antagonist macitentan in a phase III clinical trial called SERAPHIN to achieve the main target. The large, randomized, controlled study randomized 742 patients with pulmonary hypertension (PAH) to placebo at a 1: 1: 1 ratio